FirstWord: Market Research Reports

... ? The answers to these and many other questions can be found in MSL Teams: Field Force Size and Structure. This extensive market survey reveals the insights ...

... to US infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection (HCV). Clearly some of these options are achieving greater levels ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by ...

... infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection (HCV). Clearly some of these options are achieving greater levels of ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by ...

... intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the ... thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer? Do KOLs hold any other concerns about dual immunotherapy combinations ...

... events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza ...

... key opinion leader (KOL) views on recent developments in the chronic lymphocytic leukaemia (CLL) market. Topics covered include: full results from the Phase ... Imbruvica (ibrutinib; Janssen Biotech/AbbVie) in patients with high-risk CLL. Business Questions: In light of the positive results for Venclexta/Rituxan ...

... ipilimumab for the treatment of patients with anti-PD-1 refractory metastatic melanoma; and views on the results of a Phase II study investigating ... Iovance Biotherapeutics’ LN-144 for the treatment of metastatic melanoma. Business Questions: Do KOLs anticipate the results of the EORTC1325/ ...

... (golimumab; Merck Sharp & Dohme) Exploring Important Market Access Issues Market Access Impact: Ulcerative Colitis (EU5) explores key issues affecting Ulcerative Colitis drug manufacturers. You’ll learn: How barriers ...

... your brand can do to level the playing field in Market Access Impact: Ulcerative Colitis (US) [2018]. Based on a survey of 100 ... Janssen Biotech) Exploring Market Access Barriers Market Access Impact: Ulcerative Colitis (US) [2018] explores key issues affecting Ulcerative Colitis drug manufacturers. You’ll ...

... the market leader In the EU5, several of the Type 2 Diabetes Mellitus medical affairs teams we surveyed are running neck and neck with ... ways you can improve your medical affair services in Medical Affairs Reputations: Type 2 Diabetes Mellitus (Orals) (EU5). Comparing 9 major Type 2 Diabetes Mellitus (Orals) ...

... the ways you can improve your medical affairs services in Medical Affairs Reputations: Type 2 Diabetes Mellitus (Orals) (US). Comparing 9 major oral Type 2 Diabetes Mellitus treatments from AstraZeneca ...

... presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab ...

... presents key opinion leader (KOL) views on recent developments in the non-small cell lung cancer (NSCLC) market. Topics covered include: the success of the Phase ... Avastin (bevacizumab) plus chemotherapy in the first-line treatment of advanced non-squamous NSCLC at the ESMO Immuno Oncology Congress 2017; Bristol ...

... (KOLs) from North America and Europe on a variety of recent events in NASH market, including; Intercept Pharmaceuticals announcing the initiation of the global ... do KOLs say? How do KOLs arte the development of elafibranor in paediatric NASH? What concerns do experts have with elafibranor in children? What are ...

... leading brands compare to its competitors? NPS+ Haemophilia B (EU5) gives a unique insight into the ... the pack. In Europe, 2 of the 6 brands surveyed obtained a positive NPS, with one brand ... conducted the survey between February 6-19, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed ...

... ‘useful but very expensive’? Explore Important Brand Loyalty Issues NPS+ Haemophilia B (US) offers valuable insight into brand loyalty from the ... in the world. We conducted the survey between February 6-19, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered ...

... leader (KOL) insights on the latest events happening in Systemic Lupus Erythematosus (SLE) treatment landscape. Topics covered include expert opinions on the ... study investigating Stelara (ustekinumab; Janssen Biotech) for the treatment of SLE, and the potential for XTL Biopharmaceuticals’ edratide as well as ...

... Zejula (niraparib; Tesaro/Merck & Co.) for the treatment of recurrent ovarian cancer, irrespective of BRCA mutation or biomarker status; Clovis’s supplemental New ... (Rubraca) as a maintenance therapy for platinum-sensitive, recurrent ovarian cancer and for women showing a complete or partial response to platinum ...

... and Europe on a variety of recent events in Alzheimer’s disease (AD) market, including; Novartis and Amgen, together with ... the Banner Alzheimer’s Institute, launching a new Phase II/III ... are the key barriers to research into disease prevention and modification? How does CNP520 ...

... $$$ pour into digital health projects, the scope and scale of tech giants' ambitions in health become ever clearer. From ... health areas are being targeted by tech giants? Are big tech companies vying for the same opportunities? Is any tech company poised to become a dominant force in digital health? Tech ...

... and many other questions can be found in Charting the Global Biosimilars Pipeline. This comprehensive report provides the most detailed evaluation ... biosimilar companies Biosimilar pipeline by product BIOSIMILAR PIPELINE BY PRODUCT Each biosimilar monograph utilises well-structured tables and charts to provide ...

... payers at the forefront of the pricing debate are shared in Pricing and Reimbursement in Neurology. Move beyond the general comments ... for this report Pricing and Reimbursement in Neurological Diseases Pricing Issues in the EU Pricing Issues in the US Evidence Requirements for Reimbursement Decisions EU Payers ...

... anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year ... Introduction Pricing and reimbursement in Europe and the US Cancer drug spend Pricing and reimbursement mechanisms Key Insights Determination of drug price and reimbursement status ...

... patients with newly diagnosed, high-risk, metastatic hormone-sensitive prostate cancer (mHSPC); Bavarian Nordic’s announcement that it was discontinuing ... Xofigo (radium-223 dichloride) in combination with J&J's Zytiga in patients with prostate cancer as a result of an imbalance of more fractures and deaths in ...

... presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include: Takeda and Portal Instruments announcing ...

... is proving difficult. And with only 415 orphan drugs in the marketplace, it's still early days. The ROI of Orphan Drugs: Ensuring Optimal Returns centres on the commercial ...

... America and Europe on a variety of recent events in the atopic dermatitis (AD) market, including; Vanda Pharmaceuticals’ announcement of results from an ... monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis; Sanofi and Regeneron’s announcement of positive results from the Phase ...

... US and EU key opinion leader (KOL) views on recent developments in the CAR-T therapy space. Topics covered include expert opinions on the FDA approvals ... TRANSCEND study and also offer their candid insights on allogeneic CAR-T therapies such as Cellectis and Servier/Pfizer’sUniversal Chimeric Antigen Receptor ...

... ) from North America and Europe on a variety of recent events in the colorectal cancer (CRC) market, including; Symphogen announcing detailed results from its ...

... key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; expert opinions on Vertex Pharmaceuticals’ ... the FDA and EMAfor tezacaftor/ivacaftor, a second-in-class cystic fibrosis transmembrane conductance regulator (CFTR), which has been granted Priority ...

... key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of top-line ... -039 and CA204142? Is there a future for PD-1/PD-L1-based combinations in multiple myeloma? What do experts expect from BioLineRx’s Phase III GENESIS trial ...

... Medicines Agency (EMA) approval of AVEO Oncology’s Fotivda (tivozanib) in advanced RCC; the US FDA extending the approval of Pfizer’s Sutent (sunitinib) to ... - and poor-risk patients with previously untreated advanced or metastatic RCC? What factors are anticipated to impact Opdivo/ipilimumab’s chances of ...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Boehringer Ingelheim’s November 2017 announcement that the European Commisssion had granted approval for the company’s adalimumab ...

Gain new key opinion leader (KOL) insights on the latest events happening in T2DM. Topics covered include; expert views on Novo Nordisk’s recently approved once-weekly GLP-1 agonist, semaglutide (Ozempic); opinions on the results of the Phase IIIb/IV EXSCEL study which is assessing the cardiovascular (CV) ...

... Health, Cloud Pharmaceuticals, Deep Genomics, EchoBox, Numerate, Seldon, twoXAR, WuXi and NextCODE Expert Artificial Intelligence Contributors The report ... companies such as Cloud Pharmaceuticals, Benevolent Bio and Kadmon Group. AI in pharma Key insights What is artificial intelligence and machine learning? ...

... believe companies need to choose 'a road less travelled'? Commercialisation of Biosimilars: Team Tactics & Strategies Across the Product Lifecycle reveals what ... to optimal strategy development and implementation for biosimilars Key insights As the biosimilar market matures, commercial strategies will evolve to ...

... (insulin degludec/liraglutide; Novo Nordisk) Exploring Market Access Barriers Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (EU5) explores key issues affecting drug manufacturers. You ...

... from you, and what you can do to win it back, in Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US). Based on a survey of 100 ... ) Xultophy (insulin degludec/liraglutide; Novo Nordisk) Exploring Market Access Barriers Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) explores key ...

... from you, and what you can do to win it back, in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US). Based on a survey of 100 ... AstraZeneca) Tradjenta (linagliptin; Eli Lilly/Boehringer Ingelheim) Exploring Market Access Barriers Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) explores key ...

... /Boehringer Ingelheim) Vipidia (alogliptin;Takeda) Exploring Market Access Barriers Market Access Impact: Type 2 Diabetes Mellitus (Orals) (EU5) explores key issues affecting drug manufacturers. You ...

... both big pharma and small biotechs continue to invest in Alzheimer’s disease R&D. Is the amyloid hypothesis dead or could the right drug ... of Internal Medicine and Geriatrics, Toulouse University Hospital; Head of Alzheimer Disease Clinical Research Centre, University of Toulouse, France Bengt Winblad, ...

Commercialisation of Biologics: Benchmarking Leading Players It’s clear that the rapidly growing biologics sector holds a wealth of promise. The significant opportunities resulting from ...

... in customer engagement The need to deliver better customer experiences Understanding customer engagement behaviour Strategies for customer engagement: The quest for a new model Customer segmentation for efficient customer engagement strategies Benchmarking pharma companies on customer engagement ...

... survey of 150 neurologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of Parkinson's Disease medical affairs teams still has a way to ... more of; and why some are dissatisfied. Use Medical Affairs Reputations: Parkinson's Disease 2017 (EU5) to discover how your team can better meet ...

... survey of 150 rheumatologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of rheumatoid arthritis medical affairs teams still has a way ... more of; and why some are dissatisfied. Use Medical Affairs Reputations: Rheumatoid Arthritis 2017 (EU5) to discover how your team can better meet ...

... want to see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Parkinson's Disease 2017 (US) to discover how your team can better meet ...

... ? How well does your Rheumatoid Arthritis medical affairs team performance compare with the rest? Use Medical Affairs Reputations: Rheumatoid Arthritis 2017 (US) to discover how ...

... does each of the leading brands compare to its competitors? NPS+ Multiple Myeloma (EU5) gives a unique insight into the overall brand health of 7 leading ... ) Explore Important Brand Loyalty Issues NPS+ Multiple Myeloma (EU5) gives you clear and independent insight into myeloma brand loyalty from the doctors ...

... to US oncologists and haematologists to treat multiple myeloma. Clearly some of these options are achieving ... the leading brands compare to its competitors? NPS+ Multiple Myeloma (US) gives a unique insight into the ... Issues NPS+ Multiple Myeloma (US) gives you clear and independent insight into myeloma brand ...

... Zytiga or Xtandi? Is the jury still out on immunotherapies in prostate cancer? Do KOLs believe that vaccine-based therapies or PD-1/PD-L1 checkpoint inhibitors ... Honorary Consultant in Clinical Oncology and Prostate Cancer Translational Research at The Institute of Cancer Research and The Royal Marsden, London ...